Therapeutics
Developing Next Generation Therapeutics for Healthy Life
Immuno-Oncology
VIEW MORE
  1. Direct Killing
  2. CTLA4-eADCC

    HBM4003

  3. CCR8-eADCC

    HBM1022

  4. CD25-eADCC

    HBM1039

  5. MSLN-ADC

    HBM9033

  6. CEACAM-ADC

    HBM1053

  1. Overcome Immune Suppression
  2. CD73

    HBM1007

  3. B7H7

    HBM1020

  4. CD200R1

    HBM1047

  5. SigLec-7/9

    HBM1057

  6. CD36

    HBM1055

  7. LIFR

    HBM9014

Stimulate Immune Cells

T Cell Engager

  • CD3 HBICE®

  • BCMAxCD3

    HBM7020

    BCMAxCD3

  • B7H4xCD3

    HBM7004

  • CLDN18.2xCD3

    AZD5863/HBM7022

    CLDN18.2xCD3

  • CD28 HBICE®

  • PDL1xCD28

    HBM7024

  • BiKE

  • NKp30 HBICE®

  • ROR1xNKp30

    HBM7025

  • BiME/BiDE

  • CD40 HBICE®

  • PDL1xCD40

    HBM9027

  • 5T4xCD40

    HBM7023

  • T and NK

  • Other HBICE®

  • CD122xCD132

    HBM1040

  • CRTAM

    HBM1054

Direct Killing:

Deplete Treg cells or Tumor cells by eADCC and next-gen ADC technology

Stimulate Immune Cells:

By Immune Cell Engager Bispecific, e.g. HBICE® technology

Overcome Immune Suppression:

Modulate alternative immune evasion pathways beyond PD-(L)1 using H2L2/HCAb/SBC technology
Immunology
VIEW MORE